the pharmaceutical giant Merck announced Monday by U.S. partnership with Qiagen and the Government of Rwanda was in a new program of vaccination of girls and women of the screen for cervical cancer.
Merck said that it is a gift of two million doses of Gardasil vaccine to be administered to girls aged 12 to 15 while Qiagen would provide 250,000 free HPV testing for women 35 to 45 years of testing.
The objectives of the program supported by the Government of Rwanda to fight against the cancer of the cervix, which is the most common cancer among women in the African nation and is usually caused by two types of sexually transmitted human papillomavirus (HPV).
"It is our goal to create a comprehensive coordinated programme which includes vaccination against HPV, HPV-DNA analyses and treatment in order to address the nation needs unmet health services related to cervical cancer."", in cancer screening", said a statement by Richard SeziberaMinistre of Rwanda to health.
"This vaccination and screening program brings us a little more about our goal to protect girls and women in our country."
Cervical cancer strikes about 500,000 worldwide each year, particularly in poor countries where PAP is infrequent. It is regarded as the cancer the second most common among women in the world after breast cancer.
"More than eighty five percent of cervical cancer cases occur in the poorest countries of the world, having an impact on affected women, their families and their communities", said Mark Feinberg, Director of public health and scientific officer at Merck vaccines.
"Reduce the incidence of cervical cancer is a very important objective of public health."
No comments:
Post a Comment